TCM
FLGT icon

Triumph Capital Management’s Fulgent Genetics FLGT Stock Holding History

Triumph Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82 Hold
4
– – ﹤0.01% 1831
2026
Q1 		$64 Hold
4
– – ﹤0.01% 1811
2025
Q4 		$105 Buy
+4
New +$104 ﹤0.01% 1739

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Triumph Capital Management's FLGT Position: Q2 2026 in Review

Triumph Capital Management held its Fulgent Genetics (FLGT) position steady in Q2 2026 at 4 shares worth $82. The position accounts for ﹤0.01% of the portfolio, ranked #1831.

Triumph Capital Management first reported a position in FLGT in Q4 2025 and has held it in 3 quarters since. The position peaked at $105 in Q4 2025. 142 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Triumph Capital Management held 4 shares of Fulgent Genetics worth $82 as of Q2 2026.
  • Triumph Capital Management left its Fulgent Genetics share count unchanged in Q2 2026.
  • Fulgent Genetics made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1831 holding.
  • Triumph Capital Management first reported a position in Fulgent Genetics in Q4 2025 and has held it in 3 quarters since.
  • Triumph Capital Management's Fulgent Genetics position peaked at $105 in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.